[{"orgOrder":0,"company":"Respira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vardenafil Hydrochloride","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Respira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Respira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Respira Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Vardenafil

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : RT234-PAH, based on its rapid onset of action, extended duration of action, and minimal safety and tolerability issues when used in addition to PAH maintenance therapies may allow patients to acutely relieve their episodic symptoms of PAH and improve the...

                          Brand Name : RT234-PAH

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 16, 2020

                          Lead Product(s) : Vardenafil Hydrochloride

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank